undamentalytics Newsletter
Sign in

Revvity (RVTY) stock

Add to watchlist

Add holding +

NYSE: RVTY NYSE Health Care Equipment

B Fundamentals grade

Revvity is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$66

Cash-flow model

Base case. Range ~$45–$95 across our lower- and higher-growth cases (-2.5%–7.5% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 60% below it.

Price used: $166.47, November 3, 2026

Revvity valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Revvity files

Where Revvity stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $2.91bn, up 4.1% on a year earlier, slower than 4.8% a quarter earlier. That puts it 15 of 15 for growth among the health care equipment companies we cover. Free-cash-flow margin rose to 19.2% from 18.0% a year earlier. The diluted share count is down 6.2% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 7 financial-health checks. Our cash-flow model value is $59.13 a share, against a share price of $156. At that price, our model says the market is pricing in about 17.5% a year of cash-flow growth for five years, faster than the -5.3% a year revenue growth it has delivered.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Revvity's trailing-twelve-month revenue grew 4.1% year on year, with a free-cash-flow margin of 19.2%. Where it stands out: stock pay as % of revenue of 0.3% ranks 1 of 123 health care equipment companies we cover. Where it lags: days sales outstanding of 89 days ranks 102 of 118 health care equipment companies we cover.

Our discounted-cash-flow model values the business at ~$66 per share in the base case (~$45–$95 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 11.0% while net income fell 16.7%: a 28pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 6.2% in a year, so each share owns more of the business.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Priced above our value. The share price of $151.60 is 56% above our value per share of $66.
  • High earnings multiple. The shares trade at 72 times the last 12 months' earnings, so expectations are demanding.
  • Gross margin slipping. Gross margin is down 3.5 points on a year ago.
  • Below peers: days sales outstanding. Days sales outstanding of 89 days ranks 102 of 118 health care equipment companies we cover (median 57 days).

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
$1.41 against an average estimate of $1.22: beat by 15.9%
Revenue
$730m, up 1.3% on a year earlier
Share reaction
-0.2% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Guidance given
total revenue $2.83bn to $2.86bn (full year 2026); pro forma organic revenue growth growth 4% to 5% (full year 2026)
Next report
November 3, 2026; average EPS estimate $1.30

Revvity's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+9.8%
  • 1 week+2.8%
  • 1 month+9.9%
  • This year+57.1%
  • 1 year+79.5%
  • 5 years-2.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.9B
Operating margin
12.3%
Net margin
8.2%
EPS (TTM, diluted)
$2.10

Growth

Revenue growth
+4.1%
Change in growth rate
−0.7 pts
Share count change
−6.2%

Cash

Free cash flow (TTM)
$558M
FCF margin
19.2%
Stock pay % of revenue
0.3%

Earnings

Last results
August 4, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Our research
  3. Dividend
  4. Product
  5. Announcement
  6. Announcement
  7. Product
  8. Insider trade
  9. Results
  10. Guidance
  11. Announcement
  12. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Revvity valuation models and calculator

What the price is pricing in

The share price implies about 16.3% a year of cash-flow growth for five years.That is faster than the -5.3% a year revenue growth Revvity has delivered.

  • Priced in16.3%
  • Last 12 months4.1%
  • 3 years a year0.9%
  • 5 years a year-5.3%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($166.38, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$66
Price used
$166.38close November 3, 2026
Implied change
▼ 60%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Revvity's free cash flow after stock-based pay with after-tax interest added back ($560M, FY2026 Q2 TTM), growing 1.1% and 3.5% in the next two years (forecasts, guidance and its record), then back to 2.5% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$45–~$95 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Revvity's free cash flow after stock-based pay ( $560M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Revvity as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.96 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$66 ~$45–$95 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$97 ~$85–$160 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$43 ~$28–$65 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$35 ~$30–$41 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$61 ~$35–$97 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Revvity with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −31%
  • Revenue growth 5 points higher ▲ +40%
  • Free-cash-flow margin 1 point lower ▼ −6%
  • Last year's free-cash-flow margin change, if it persists ▲ +7%
  • Discount rate 1 point higher ▼ −18%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $53$79$113$158$217$293
8.5% $36$54$79$112$154$208
10% $25$40$59$84$116$157

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$51.82$50.72$71.43$75.77$95.45$141.52$198.66$138.80$108.45$111.40$96.51$151.60
Market value$5.9bn$5.6bn$7.9bn$8.5bn$10.6bn$15.9bn$23.2bn$17.5bn$13.5bn$13.7bn$11.3bn$17.1bn
+ Net debt (− = net cash)$775m$687m$1.8bn$1.7bn$1.9bn$1.6bn$4.4bn$4.0bn$3.0bn$2.0bn$2.3bn$2.2bn
Enterprise value$6.6bn$6.3bn$9.7bn$10.2bn$12.5bn$17.5bn$27.6bn$21.5bn$16.6bn$15.7bn$13.6bn$19.3bn
Multiples
Price / sales 2.8x2.6x3.5x3.0x3.7x4.2x6.1x5.3x4.9x5.0x3.9x5.9x
Price / earnings 27.6x23.9x27.1x35.5x46.8x21.8x24.6x30.8x19.5x50.6x46.7x72.1x
Price / free cash flow 22.7x17.5x31.8x38.8x37.1x19.1x17.5x29.5xn/m25.3x22.1x30.7x
EV / EBITDA 18.7x15.9x24.3x20.2x21.7x16.4x17.6x18.4x22.6x20.3x17.8x32.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

70 /100

Moderate moat

How hard Revvity's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 11 / 20

    Cash operating profit has been a median 8.9% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 48.1%, moving by 6.3 percentage points (standard deviation) across 10 years.

  • Durability 13 / 20

    Operating margin has been a median 13.3%; its worst year was 10.2%.

  • Cash conversion 17 / 20

    Free cash flow was positive in 10 of 10 years, at a median 14.5% of revenue.

  • Discipline 17 / 20

    The diluted share count rose 0.5% over five years; stock-based pay has been a median 0.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $5.35 +6% $2.9bn −0%
Next $5.89 +10% $3.0bn +5%

Next year's EPS estimate has moved +1.2% in 90 days, across 17 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.0% on 90 days ago. In the last 30 days, 2 analysts raised Revvity's forecast and 0 cut it.

Consensus EPS forecast Revvity, last 90 days
$5.20 $5.40 $5.60 $5.80 $6.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $5.24 Current fiscal year, 60 days ago: $5.35 Current fiscal year, 30 days ago: $5.35 Current fiscal year, 7 days ago: $5.35 Current fiscal year, Now: $5.35 $5.35 Next fiscal year, 90 days ago: $5.83 Next fiscal year, 60 days ago: $5.89 Next fiscal year, 30 days ago: $5.89 Next fiscal year, 7 days ago: $5.89 Next fiscal year, Now: $5.89 $5.89

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $5.24$5.83
60 days ago $5.35$5.89
30 days ago $5.35$5.89
7 days ago $5.35$5.89
Now $5.35$5.89

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $1.22 $1.41 +15.9%
Mar 2026 $1.01 $1.06 +4.5%
Dec 2025 $1.58 $1.70 +7.8%
Sept 2025 $1.14 $1.18 +3.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026
  • total revenue full year 2026 $2.83bn to $2.86bn Raised
    “For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.” source
  • pro forma organic revenue growth full year 2026 4% growth to 5% growth Non-GAAP Raised
    “For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.” source
  • pro forma adjusted earnings per share full year 2026 $5.30 to $5.40 Non-GAAP Raised
    “For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Revvity's revenue by +1.1% next year and +3.5% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+0.7%, weight 56%) , management guidance (+0.5%, weight 19%) and the company's own record (+2.5%, weight 25%) . How the weights are set.

Analyst recommendations

18 analysts, Oct 2026
Buy633%
Hold1161%
Sell16%

Monthly trend

  1. Oct 202661118
  2. Sep 202651117
  3. Aug 202661117
  4. Jul 202661117

Counts of recommendations published by analysts covering Revvity, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.6%
of tradable shares
Days to cover
2.82
at average volume
Short interest, 1 month
+3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.3%
of shares
Employees
11,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +62.4%

$93.36 on October 31, 2025 to $151.60

ThenNowEffect
Revenue (last 12 months) $2.8bn $2.9bn +4.1%
Net margin 10.2% 8.2% −19.9%
P/E multiple 39.4x 72.1x +82.8%
Share count 121m 113m +6.6%

Biggest factor: p/e multiple.

Last 3 years +73.3%

$87.47 on November 3, 2023 to $151.60

ThenNowEffect
Revenue (last 12 months) $2.8bn $2.9bn +2.6%
Net margin 28.8% 8.2% −71.7%
P/E multiple 13.5x 72.1x +434.9%
Share count 126m 113m +11.6%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
RVTY+40%−30%−22%+2%−13%+57%
Industry peers (median)−9%−37%−8%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
RVTY83%50%42%33%42%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
RVTY−25%−42%−43%−15%−35%−30%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 59% from December 31, 2021 to October 30, 2023. Getting back needed a 144% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$82.17 – $165.78
From 52-week high
−8.6%
vs 50-day average
+4.6%
vs 200-day average
+35.4%
Volatility (1 year)
39%
Beta vs S&P 500
1.18

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±5.4%
After a week
6 up, 6 down
typical move ±6.4%
After a month
5 up, 7 down
typical move ±8.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 −0.2% +1.6% +0.4% +13.6%
May 5, 2026 +14.5% +2.2% +14.8% +18.4%
February 2, 2026 −7.0% −0.4% −5.5% −9.5%
January 13, 2026 +7.3% −0.7% +12.2% −8.0%
October 27, 2025 −2.5% +1.4% −6.0% +6.8%
July 28, 2025 −8.9% −0.3% −14.8% −12.0%
April 28, 2025 +0.4% +0.7% −1.5% −3.1%
January 31, 2025 −2.5% −1.2% −6.3% −13.9%
January 13, 2025 +6.0% +0.3% +8.9% −2.2%
November 4, 2024 +4.1% +1.0% −0.3% −4.1%
July 29, 2024 +10.4% −0.4% +4.4% +6.3%
April 29, 2024 +0.9% −1.2% +1.3% +8.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Revvity’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Revvity in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Revvity
$2.7B $2.8B $2.9B $3B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $2.8B Revenue (TTM), FY23 Q4: $2.8B Revenue (TTM), FY24 Q1: $2.7B Revenue (TTM), FY24 Q2: $2.7B Revenue (TTM), FY24 Q3: $2.7B Revenue (TTM), FY24 Q4: $2.8B Revenue (TTM), FY25 Q1: $2.8B Revenue (TTM), FY25 Q2: $2.8B Revenue (TTM), FY25 Q3: $2.8B Revenue (TTM), FY25 Q4: $2.9B Revenue (TTM), FY26 Q1: $2.9B Revenue (TTM), FY26 Q2: $2.9B $2.9B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $2.8B
FY23 Q4 $2.8B
FY24 Q1 $2.7B
FY24 Q2 $2.7B
FY24 Q3 $2.7B
FY24 Q4 $2.8B
FY25 Q1 $2.8B
FY25 Q2 $2.8B
FY25 Q3 $2.8B
FY25 Q4 $2.9B
FY26 Q1 $2.9B
FY26 Q2 $2.9B
Revenue growth, TTM YoY Revvity
-30% -20% -10% 0% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -22.3% Revenue growth, TTM YoY, FY23 Q4: -16.9% Revenue growth, TTM YoY, FY24 Q1: -9.9% Revenue growth, TTM YoY, FY24 Q2: -4.5% Revenue growth, TTM YoY, FY24 Q3: -2.7% Revenue growth, TTM YoY, FY24 Q4: 0.2% Revenue growth, TTM YoY, FY25 Q1: 1.6% Revenue growth, TTM YoY, FY25 Q2: 3.3% Revenue growth, TTM YoY, FY25 Q3: 3.4% Revenue growth, TTM YoY, FY25 Q4: 3.7% Revenue growth, TTM YoY, FY26 Q1: 4.8% Revenue growth, TTM YoY, FY26 Q2: 4.1% 4.1%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -22.3%
FY23 Q4 -16.9%
FY24 Q1 -9.9%
FY24 Q2 -4.5%
FY24 Q3 -2.7%
FY24 Q4 0.2%
FY25 Q1 1.6%
FY25 Q2 3.3%
FY25 Q3 3.4%
FY25 Q4 3.7%
FY26 Q1 4.8%
FY26 Q2 4.1%
Operating margin (TTM) Revvity
9% 10% 11% 12% 13% 14% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 12.9% Operating margin (TTM), FY23 Q4: 10.9% Operating margin (TTM), FY24 Q1: 9.9% Operating margin (TTM), FY24 Q2: 10.2% Operating margin (TTM), FY24 Q3: 11.2% Operating margin (TTM), FY24 Q4: 12.6% Operating margin (TTM), FY25 Q1: 13.5% Operating margin (TTM), FY25 Q2: 13.6% Operating margin (TTM), FY25 Q3: 12.9% Operating margin (TTM), FY25 Q4: 12.5% Operating margin (TTM), FY26 Q1: 12.4% Operating margin (TTM), FY26 Q2: 12.3% 12.3%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 12.9%
FY23 Q4 10.9%
FY24 Q1 9.9%
FY24 Q2 10.2%
FY24 Q3 11.2%
FY24 Q4 12.6%
FY25 Q1 13.5%
FY25 Q2 13.6%
FY25 Q3 12.9%
FY25 Q4 12.5%
FY26 Q1 12.4%
FY26 Q2 12.3%
FCF margin (TTM) Revvity
-10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -1.8% FCF margin (TTM), FY23 Q4: 0.4% FCF margin (TTM), FY24 Q1: 3.6% FCF margin (TTM), FY24 Q2: 14.1% FCF margin (TTM), FY24 Q3: 20.7% FCF margin (TTM), FY24 Q4: 19.7% FCF margin (TTM), FY25 Q1: 18.9% FCF margin (TTM), FY25 Q2: 18.0% FCF margin (TTM), FY25 Q3: 17.7% FCF margin (TTM), FY25 Q4: 17.8% FCF margin (TTM), FY26 Q1: 17.0% FCF margin (TTM), FY26 Q2: 19.2% 19.2%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -1.8%
FY23 Q4 0.4%
FY24 Q1 3.6%
FY24 Q2 14.1%
FY24 Q3 20.7%
FY24 Q4 19.7%
FY25 Q1 18.9%
FY25 Q2 18.0%
FY25 Q3 17.7%
FY25 Q4 17.8%
FY26 Q1 17.0%
FY26 Q2 19.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Revvity took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $2.9B
  2. Research and development $216M · 7.6%
  3. Selling, general and admin $992M · 34.7%
  4. Other operating costs $1.3B · 45.2%
  5. Operating income $357M · 12.5%
  6. Income tax $28.4M · 1.0%
  7. Interest and other $87M · 3.0%
  8. Net income $241M · 8.4%

Shares of revenue. Source: Revvity's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Jan 2010 2010 Jan 2011 2011 Jan 2012 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Jan 2016 2016 Jan 2017 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Jan 2021 2021 Jan 2022 2022 Jan 2023 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jul 2026
Income
Revenue 1,551 1,704 1,919 2,115 2,158 2,237 2,105 2,116 2,257 2,778 2,884 3,783 3,828 3,312 2,751 2,755 2,856 2,912
Gross profit 699 761 848 963 976 1,005 964 1,013 1,074 1,341 1,396 2,110 2,434 1,990 — — — —
EBITDA 197 247 202 228 355 275 356 395 401 504 576 1,069 1,570 1,170 732 775 762 602
Operating income 116 158 91 103 228 165 251 295 296 324 362 867 1,258 743 301 347 357 359
Net income 82 391 8 70 167 158 212 234 293 238 228 728 943 569 693 270 241 238
Diluted EPS $0.70 $3.31 $0.07 $0.61 $1.47 $1.39 $1.87 $2.12 $2.64 $2.13 $2.04 $6.49 $8.08 $4.50 $5.55 $2.20 $2.07 $2.10
Growth (year on year)
Revenue −6.6% +9.9% +12.6% +10.3% +2.0% +3.7% −5.9% +0.5% +6.7% +23.1% +3.8% +31.2% +1.2% −13.5% −16.9% +0.2% +3.7% +4.1%
EBITDA −12.6% +25.4% −18.1% +13.0% +55.4% −22.3% +29.3% +10.7% +1.5% +25.9% +14.2% +85.6% +46.9% −25.5% −37.4% +5.8% −1.6% −2.5%
Operating income −21.5% +35.9% −42.2% +13.2% +120.9% −27.6% +52.1% +17.4% +0.4% +9.6% +11.8% +139.6% +45.1% −41.0% −59.5% +15.4% +2.9% −5.5%
Net income −35.1% +376.3% −98.0% — +139.1% −5.6% +34.6% +10.3% +24.9% −18.7% −4.4% +219.9% +29.6% −39.7% +21.8% −61.0% −10.8% −16.7%
Diluted EPS −34.6% +372.9% −97.9% — +141.0% −5.4% +34.5% +13.4% +24.5% −19.3% −4.2% +218.1% +24.5% −44.3% +23.3% −60.4% −5.9% −11.2%
Margins
Gross margin 45.1% 44.7% 44.2% 45.5% 45.2% 44.9% 45.8% 47.9% 47.6% 48.3% 48.4% 55.8% 63.6% 60.1% — — — —
EBITDA margin 12.7% 14.5% 10.5% 10.8% 16.4% 12.3% 16.9% 18.7% 17.8% 18.2% 20.0% 28.3% 41.0% 35.3% 26.6% 28.1% 26.7% 20.7%
Operating margin 7.5% 9.2% 4.7% 4.9% 10.6% 7.4% 11.9% 13.9% 13.1% 11.7% 12.6% 22.9% 32.9% 22.4% 10.9% 12.6% 12.5% 12.3%
Net margin 5.3% 22.9% 0.4% 3.3% 7.8% 7.1% 10.1% 11.1% 13.0% 8.6% 7.9% 19.2% 24.6% 17.2% 25.2% 9.8% 8.4% 8.2%
Free-cash-flow margin 7.9% 7.7% 10.1% 5.2% 5.5% 11.4% 12.3% 15.1% 11.0% 7.8% 10.0% 21.9% 34.6% 17.9% 0.4% 19.7% 17.8% 19.2%
Cash flow
Cash from operations 149 164 225 152 159 282 287 351 288 311 363 892 1,411 680 91 628 583 628
Capital spending 26 34 31 42 39 27 28 32 39 93 76 64 86 86 81 87 74 70
Free cash flow 123 131 194 110 120 254 259 319 249 218 287 829 1,325 594 10 542 509 558
Stock-based pay 14 12 15 21 14 14 17 17 25 29 32 27 30 52 41 38 23 10
Free cash flow after stock pay 109 118 179 89 106 240 242 302 224 189 256 802 1,295 543 −32 504 487 548
Balance sheet
Cash 180 420 142 173 175 175 238 359 202 163 192 387 603 454 913 1,163 920 1,023
Total debt 558 426 948 941 935 1,053 1,013 1,046 2,006 1,891 2,074 2,009 5,027 4,429 3,927 3,172 3,239 3,222
Net debt (negative = net cash) 378 6 806 767 760 878 775 687 1,804 1,728 1,882 1,622 4,424 3,975 3,014 2,009 2,320 2,199
Diluted shares 117m 118m 114m 115m 114m 114m 113m 110m 111m 112m 112m 112m 117m 126m 125m 123m 117m 113m
Returned to shareholders
Dividends 33 33 32 32 32 32 32 31 31 31 31 31 32 35 35 34 33 32
Buybacks 15 73 110 2 127 66 76 152 4 57 6 7 73 81 389 370 821 476
Total returned 47 106 142 34 159 97 108 183 35 88 37 38 105 116 424 404 854 508

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · July 5, 2026
What it owns · $12.0bn
Short-term assets $2.3bnLonger-term assets $9.7bn
What it owes, and who funded it · $12.0bn
Short-term liabilities $1.3bnLonger-term liabilities $3.5bnShareholders' equity $7.2bn
  • Short-term assets cover short-term liabilities $2.3bn of assets due within a year against $1.3bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2.3bn short-term assets against $3.5bn of longer-dated liabilities.
  • More cash than debt $1.0bn of cash against $3.2bn of debt.
  • Debt below 40% of shareholders' equity Debt is 44% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 70% to 44% over five years.
  • A year's operating cash flow covers at least 20% of debt $628m of operating cash flow against $3.2bn of debt.
  • Operating profit covers interest at least five times over Operating income of $359m against $94m of interest.

From Revvity's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$476M
Dividends (TTM)
$31.7M
Returned to shareholders
91%
of free cash flow
Buybacks, last 3 fiscal years
$1.6B
Diluted share count
−6.2%
year over year
Total shareholder yield
3.0%
dividends 0.2% + buybacks 2.8% of market value
Dividend payout ratio
13%
of net income paid out
R&D spending
7.4%
of revenue
Sales & admin spending
35.2%
of revenue
Days sales outstanding
89 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated RVTY PODD GMED QDEL ENOV TFX Median
Revenue, last 12 months $2.9bn $3.1bn $3.1bn $2.7bn $2.3bn $2.3bn $99m
Revenue growth, last 12 months 4.1% 29.4% 19.7% −2.5% 4.9% 30.7% 9.2%
Revenue growth, 3-year average 0.9% 27.7% 42.1% −5.4% 12.2% −8.0% 13.5%
Revenue growth, latest quarter 1.3% 23.5% 5.9% 2.8% 3.2% 28.9% 10.2%
Gross margin 60.1% 71.1% 68.5% — 61.1% 54.9% 61.2%
Operating margin 12.3% 16.9% 20.3% −30.8% −45.1% 2.0% −8.5%
Operating margin, 3-year average 12.0% 16.2% 11.4% −34.4% −28.5% 5.7% −17.9%
Net margin 8.2% 12.3% 17.0% −39.2% −48.0% −45.8% −12.0%
Cash from operations / revenue 21.6% 16.7% 28.9% −2.1% 11.8% 10.8% −1.9%
Free-cash-flow margin 19.2% 9.0% 24.0% −7.9% 2.8% 7.5% −3.9%
Free-cash-flow margin, 3-year average 17.1% 11.6% 17.1% −4.5% −0.2% 7.7% −7.0%
Stock pay / revenue 0.3% 2.6% 1.6% 1.7% 1.5% 1.1% 6.1%
Change in share count −6.2% −3.6% −1.4% 0.9% 1.7% −4.0% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 4.1% 9.1% 86 of 129
Change in growth rate Growth -0.7pp -0.6pp 68 of 129
Operating margin Profitability 12.3% -8.3% 25 of 132
Net margin Profitability 8.2% -12.0% 32 of 133
Free-cash-flow margin Cash generation 19.2% -3.4% 13 of 128
Stock pay as % of revenue Cash generation 0.3% 6.1% 1 of 123
Long-term debt as % of assets Balance sheet 21.9% 24.2% 42 of 87
Change in share count Balance sheet -6.2% 3.3% 5 of 115
Days sales outstanding Balance sheet 89 days 57 days 102 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 28, 2025
Segments
Line of business Revenue Share YoY
Life Sciences $1.4B 50.1% ▲ 2.3%
Diagnostics $1.4B 49.9% ▲ 5.1%
Products and services
Line of business Revenue Share YoY
Products $2.4B 83.7% ▲ 2.2%
Services $466M 16.3% ▲ 11.8%
Geography
Region Revenue YoY
Total International $1.7B ▲ 4.4%
Americas $1.3B ▲ 2.7%
United States $1.1B ▲ 2.6%
Other International $1B ▲ 7.4%
Europe $825M ▲ 11.1%
Asia $775M ▼ 1.8%
China $425M ▼ 5.5%
Germany $178M ▲ 9.3%
United Kingdom $127M ▲ 12.4%

These categories overlap or exclude eliminations, so shares aren't shown.

From Revvity's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$12.7B
Institutions reporting
537
Shares held vs prior quarter
▼ 1.3%
Positions opened / closed
92 / 53

Top buyers and sellers, Q2 2026: 287 institutions bought and 216 sold ; the biggest buyer was Citadel Advisors LLC (+1.4M shares) and the biggest seller Price T Rowe Associates Inc (−4.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
T. Rowe Price Investment Management, Inc. $2B 18.3M 16.0% ▼ 17.7%
Jupiter Topco LLC $961M 8.6M 7.6% —
Edgepoint Investment Group Inc. $951M 8.5M 7.5% ▼ 2.9%
Blackrock, Inc. $852M 7.7M 6.7% ▲ 5.6%
Vanguard Capital Management LLC $812M 7.3M 6.4% ▼ 0.4%
Price T Rowe Associates Inc $615M 5.5M 4.9% ▼ 45.2%
Vanguard Portfolio Management LLC $531M 4.8M 4.2% ▼ 0.9%
State Street Corp $483M 4.3M 3.8% ▲ 0.8%
Victory Capital Management Inc $406M 3.6M 3.2% ▲ 8.1%
Dimensional Fund Advisors LP $381M 3.4M 3.0% ▲ 17.5%
Geode Capital Management, LLC $328M 3.0M 2.6% ▲ 0.6%
Morgan Stanley $286M 2.6M 2.3% ▼ 4.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Revvity's complete shareholder register. Values are as reported by the filers ; 5 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $6M 17 trades by 7 insiders · 99% under pre-set plans
Net ▼ $6M net selling
Insider Date Trade Shares Price Value
Gonzales Anita VP and CAO October 1, 2026 Sell pre-set plan 84 $155.48 $13,060
Krakowiak Maxwell Please See Remarks September 21, 2026 Sell pre-set plan 1,631 $144.53 $235,728
Vohra Tajinder S Please See Remarks September 16, 2026 Sell pre-set plan 7,330 $140.88 $1M
Gonzales Anita Vice President and CAO July 20, 2026 Sell pre-set plan 85 $109.48 $9,306
Gonzales Anita Vice President and CAO April 20, 2026 Sell pre-set plan 80 $92.80 $7,424
Victor Miriame Please See Remarks February 24, 2026 Sell pre-set plan 1,862 $97.13 $180,856
Mcmurry-Heath Michelle Director February 23, 2026 Sell 600 $97.26 $58,356
Goldberg Joel S Please See Remarks February 5, 2026 Sell pre-set plan 532 $102.52 $54,541
Goldberg Joel S Please See Remarks February 5, 2026 Sell pre-set plan 2,217 $101.33 $224,649
Goldberg Joel S Please See Remarks February 5, 2026 Sell pre-set plan 3,544 $100.50 $356,172
Goldberg Joel S Please See Remarks February 5, 2026 Sell pre-set plan 6,424 $99.47 $638,995
Singh Prahlad R. Please See Remarks February 5, 2026 Sell pre-set plan 1,068 $102.52 $109,491

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 15 trades and filings

In the last 12 months, 1 member of Congress disclosed 2 purchases and 3 sales of Revvity shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (partial), $15,001 - $50,000, traded September 9, 2026, filed October 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (partial), $1,001 - $15,000, traded September 4, 2026, filed October 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (partial), $1,001 - $15,000, traded September 3, 2026, filed October 12, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 1, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 5, 2026
  • February 2, 2026
  • January 13, 2026
  • October 27, 2025
  • July 28, 2025

Recent SEC filings

Data status

When each part of this page on Revvity was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Revvity in brief

What does Revvity do?
Revvity is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Revvity's stock ticker?
Revvity trades under the ticker RVTY on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Revvity's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Revvity reported revenue of $2.9B, 4.1% higher than a year earlier, according to its SEC filings.
What is Revvity's free cash flow?
Revvity's free-cash-flow margin is 19.2% of revenue over the trailing twelve months, ranking 13 of the 128 health care equipment companies we cover.
What is Revvity's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Revvity's free cash flow after stock-based pay gives ~$66 per share in the base case, and ~$45–$95 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Revvity's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are T. Rowe Price Investment Management, Inc., Jupiter Topco LLC and Edgepoint Investment Group Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Revvity buying back stock, and does it pay a dividend?
Revvity spent $476M on share repurchases over the trailing twelve months, and its diluted share count fell 6.2% over the year.
What is Revvity's market cap?
On November 2, 2026, Revvity's market capitalisation was about $17.1B, with a price-to-earnings ratio of 72.1 and net debt of $2.2B. Market figures come from third-party market data and may be delayed.
Does Revvity pay a dividend?
Yes: Revvity paid $31.7M in dividends over the trailing twelve months, a dividend yield of 0.19% and a payout ratio of 13.4%.
How much debt does Revvity have?
Revvity's debt-to-equity ratio is 44.3%, from its latest balance sheet (69.7% five years earlier). The financial health section below sets out its other solvency checks.
Who are Revvity's competitors?
In our Health Care Equipment peer group, the companies closest to Revvity are Insulet Corporation, Globus Medical Inc, Quidelortho Corp, Enovis Corp and Teleflex Inc. The side-by-side comparison below sets their revenue, margins and growth against Revvity's.
Are insiders buying or selling Revvity stock?
Over the last 12 months, Revvity's directors and officers reported 0 open-market purchases and 17 sales on Form 4. The insider trading page charts every trade.